HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.